Literature DB >> 23473088

Adenoviral keratoconjunctivitis: an update.

J J González-López1, R Morcillo-Laiz, F J Muñoz-Negrete.   

Abstract

The objective of this review is to describe the clinical and epidemiological characteristics of adenoviral conjunctivitis, as well as to present a practical update on its diagnosis, treatment and prophylaxis. There are two well-defined adenoviral keratoconjunctivitis clinical syndromes: epidemic keratoconjunctivitis and pharyngoconjunctival fever, which are caused by different adenovirus serotypes. The exact incidence of adenoviral conjunctivitis is unknown. However, cases are more frequent during warmer months. Contagion is possible through direct contact or fomites and the virus is extremely resistant to different physical and chemical agents. The symptomatology of conjunctival infection is similar to any other conjunctivitis, with a higher incidence of pseudomembranes. In the cornea, adenoviral infection may lead to keratitis nummularis. Diagnosis is mainly clinical, but its etiology can be confirmed using cell cultures, polymerase chain reaction or immunochromatography. Multiple treatments have been tried for this disease, but none of them seem to be completely effective. Prevention is the most reliable way to control this contagious infection.
Copyright © 2011 Sociedad Española de Oftalmología. Published by Elsevier Espana. All rights reserved.

Entities:  

Mesh:

Year:  2012        PMID: 23473088     DOI: 10.1016/j.oftal.2012.07.007

Source DB:  PubMed          Journal:  Arch Soc Esp Oftalmol        ISSN: 0365-6691


  11 in total

Review 1.  Peptide therapeutics for treating ocular surface infections.

Authors:  Curtis R Brandt
Journal:  J Ocul Pharmacol Ther       Date:  2014-09-24       Impact factor: 2.671

2.  [Adenoviral keratoconjunctivitis].

Authors:  U Pleyer; F Birnbaum
Journal:  Ophthalmologe       Date:  2015-05       Impact factor: 1.059

3.  Human adenovirus: Viral pathogen with increasing importance.

Authors:  B Ghebremedhin
Journal:  Eur J Microbiol Immunol (Bp)       Date:  2014-03-14

4.  Regulation of Human Adenovirus Replication by RNA Interference.

Authors:  N A Nikitenko; T Speiseder; E Lam; P M Rubtsov; Kh D Tonaeva; S A Borzenok; T Dobner; V S Prassolov
Journal:  Acta Naturae       Date:  2015 Jul-Sep       Impact factor: 1.845

Review 5.  The Repertoire of Adenovirus in Human Disease: The Innocuous to the Deadly.

Authors:  Subrat Khanal; Pranita Ghimire; Amit S Dhamoon
Journal:  Biomedicines       Date:  2018-03-07

6.  Clinical and public health management of conjunctivitis in the Israel Defense Forces.

Authors:  Orly Efros; Alon Zahavi; Hagai Levine; Michael Hartal
Journal:  Disaster Mil Med       Date:  2015-05-11

7.  1-(4-Phenoxybenzyl) 5-Aminouracil Derivatives and Their Analogues - Novel Inhibitors of Human Adenovirus Replication.

Authors:  N A Nikitenko; E S Gureeva; A A Ozerov; A I Tukhvatulin; F M Izhaeva; V S Prassolov; P G Deryabin; M S Novikov; D Y Logunov
Journal:  Acta Naturae       Date:  2018 Apr-Jun       Impact factor: 1.845

8.  Frequency of adenovirus serotype 8 in patients with Keratoconjunctivitis, in Ahvaz, Iran.

Authors:  Kolsoom Shafiei; Manoochehr Makvandi; Ali Teimoori; Alireza Samarbafzadeh; Gholamreza Khataminia; Shahram Jalilian; Niloofar Neisi; Kimia Makvandi; Mehrdad Sadeghi Haj
Journal:  Iran J Microbiol       Date:  2019-04

9.  The prevalence of adenoviral conjunctivitis at the Clinical Hospital of the State University of Campinas, Brazil.

Authors:  Roberto Damian Pacheco Pinto; Rodrigo Pessoa Cavalcanti Lira; Carlos Eduardo Leite Arieta; Rosane Silvestre de Castro; Sandra Helena Alves Bonon
Journal:  Clinics (Sao Paulo)       Date:  2015-11       Impact factor: 2.365

10.  Comparative study on the efficacy of non-steroidal, steroid and non-use of anti-inflammatory in the treatment of acute epidemic conjunctivitis.

Authors:  Luiz Alfredo Santiago; Jussara Matyelle Rodrigues da Silva; Orleâncio Gomes Ripardo de Azevedo; Paulo Roberto Leitão de Vasconcelos
Journal:  Acta Cir Bras       Date:  2020-02-07       Impact factor: 1.388

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.